哌甲酯治疗后扩散MRI显示的白质变化:一项针对注意缺陷多动障碍男性的随机对照试验
该前瞻性随机双盲安慰剂对照试验纳入50名未接受过兴奋剂治疗的男孩和49名年轻成年男性注意缺陷多动障碍患者,随机接受哌甲酯或安慰剂治疗16周,比较治疗前后扩散张量成像各向异性分数变化。基于体系的影像分析显示,仅在哌甲酯治疗的男孩中左侧半球联合纤维束及胼胝体干外侧部各向异性分数增加更明显(标准化效应量5.25),成人未见类似改变,提示该效应似乎与年龄相关。
要点
- 哌甲酯治疗4个月后,男孩左侧半球联合纤维束及胼胝体干外侧部各向异性分数增加更明显。
- 该白质微结构改变似乎与年龄相关,成年男性接受哌甲酯治疗后未观察到类似改变。
- 基于感兴趣区的各向异性分数分析未发现任何条件下时间主效应,体系分析方显示交互效应。
核心结论
- 哌甲酯治疗4个月可影响注意缺陷多动障碍男孩脑白质特定纤维束,该效应似乎与年龄相关,因为接受哌甲酯治疗的成人中未观察到这些效应。
研究设计与样本
- 前瞻性随机双盲安慰剂对照试验(ePOD-MPH),于2011年10月13日至2015年6月15日在注意缺陷多动障碍转诊中心开展。
- 纳入50名未接受过兴奋剂治疗的男孩(哌甲酯组25名、安慰剂组25名,年龄10-12岁)和49名年轻成年男性(哌甲酯组24名、安慰剂组24名,年龄23-40岁),均符合《精神疾病诊断与统计手册》第四版注意缺陷多动障碍(所有类型)诊断标准。
- 随机接受哌甲酯或安慰剂治疗16周,治疗前及停药1周后行MRI检查,包括扩散张量成像。
- 主要结局指标为各向异性分数变化,在三个感兴趣区及基于体系的脑白质分析中评估;感兴趣区分析采用意向性治疗线性混合模型,体系分析采用置换检验法并进行族系误差校正。
关键影像表现/征象
- 基于体系的扩散张量成像分析显示,左侧半球多个联合纤维束及胼胝体干外侧部存在显著(P < .05)的时间×药物×年龄交互效应。
- 该交互效应源于接受哌甲酯治疗的男孩各向异性分数增加更明显(标准化效应量5.25),接受安慰剂的男孩及成年男性中未见类似改变。
诊断标准与关键数值
- 基于感兴趣区的各向异性分数分析未发现任何条件下时间主效应。
- 基于体系的扩散张量成像分析中,左侧半球联合纤维束及胼胝体干外侧部时间×药物×年龄交互效应显著(P < .05)。
- 哌甲酯治疗男孩各向异性分数增加更明显的标准化效应量为5.25。
临床应用与阅片要点
- 解读注意缺陷多动障碍患儿扩散张量成像时,哌甲酯治疗相关的白质各向异性分数增高主要见于左侧半球联合纤维束及胼胝体干外侧部。
- 此类白质微结构改变似乎与年龄相关,在成年患者中未观察到,判读时需结合年龄与用药状态。
局限性
- 原文报告基于感兴趣区的各向异性分数分析未发现任何条件下时间主效应,效应仅见于基于体系的交互分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BackgroundMethylphenidate (MPH) is highly effective in treating attention-deficit/hyperactivity disorder (ADHD). However, not much is known about its effect on the development of human brain white matter (WM).PurposeTo determine whether MPH modulates WM microstructure in an age-dependent fashion in a randomized double-blind placebo-controlled trial (Effects of Psychotropic Medication on Brain Development-Methylphenidate, or ePOD-MPH) among ADHD referral centers between October 13, 2011, and June 15, 2015, by using diffusion-tensor imaging (DTI).Materials and MethodsIn this prospective study (NTR3103 and NL34509.000.10), 50 stimulant treatment-naive boys and 49 young adult men diagnosed with ADHD (all types) according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition criteria were randomized to undergo treatment with MPH or placebo for 16 weeks. Before and 1 week after treatment cessation, study participants underwent MRI, including DTI. The outcome measure was change in fractional anisotropy (FA), which was assessed in three regions of interest (ROIs), as well as in a voxel-based analysis in brain WM. Data were analyzed by using intention-to-treat linear mixed models for ROI analysis and a permutation-based method for voxel-based analysis with family-wise error correction.ResultsFifty boys (n = 25 MPH group, n = 25 placebo group; age range, 10-12 years) and 48 men (n = 24 MPH group, n = 24 placebo group; age range, 23-40 years) were included. ROI analysis of FA yielded no main effect of time in any of the conditions. However, voxel-based analysis revealed significant (P < .05) time-by-medication-by-age interaction effects in several association tracts of the left hemisphere, as well as in the lateral aspect of the truncus of the corpus callosum, due to greater increase in FA (standardized effect size, 5.25) in MPH-treated boys. Similar changes were not present in boys receiving a placebo, nor in adult men.ConclusionFour months of treatment with methylphenidate affects specific tracts in brain white matter in boys with attention-deficit/hyperactivity disorder. These effects seem to be age dependent, because they were not observed in adults treated with methylphenidate.© RSNA, 2019Online supplemental material is available for this article.
引用
- Bouziane C, Filatova OG, Schrantee A, et al. White Matter by Diffusion MRI Following Methylphenidate Treatment: A Randomized Control Trial in Males with Attention-Deficit/Hyperactivity Disorder. Radiology. 2019. PMID: 31407970. doi:10.1148/radiol.2019182528
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。